Continuous positive airway pressure-treated patients’ behaviours during the COVID-19 crisis

To the Editor:

Obstructive sleep apnoea (OSA) is one of the most prevalent chronic diseases, affecting nearly one billion people worldwide [1]. Continuous positive airway pressure (CPAP) is the first-line therapy for OSA [2], and is currently used by over one million people throughout France. A focus on the OSA population during the COVID-19 outbreak is of particular interest for the following two main reasons. 1) OSA is a multi-morbid disease with up to 70% of patients being obese [3] and exhibiting a high prevalence of cardiometabolic comorbidities. Such a clinical context is expected to be associated with a higher risk of severe forms of COVID-19 and a higher mortality rate [4]. 2) CPAP treatment is considered a high-risk aerosol-generating procedure potentially facilitating viral dispersion into the environment and transmission of infection [5–7]. As a result, CPAP-treated patients have often received contradictory information regarding their individual level of risk during the pandemic and ambiguous instructions as whether to continue or stop CPAP. The objective of the current study was to describe CPAP-treated patients’ beliefs and attitudes during the COVID-19 health crisis, to find out which healthcare workers had informed and supported them, and to identify changes in their CPAP treatment behaviours.

A cross-sectional online survey was sent by a non-profit organisation dedicated to quality of care and education in sleep apnoea (“Alliance apnées”) and a consortium of healthcare providers (Agiradom, Bastide, Elivie, Isis, La Poste (ASTEN), SOS Oxygène, Vitalaire), to ~110 000 CPAP-treated patients. The survey was filled out anonymously, and access to the data was restricted to study investigators only. The survey was conducted between 27 April and 17 May 2020, close to the end of lockdown and during the rapid decline in the burden of COVID-19 in France [8]. The survey contained questions on age, gender, geographic location (departments (counties in France)), family unit, and self-reported OSA severity (mild, moderate or severe). The survey questionnaire consisted of items on attitudes regarding CPAP treatment including discontinuation and changes in life habits, in particular sleeping arrangements. Participants also reported whether they had been diagnosed with COVID-19 by healthcare professionals with or without a confirmatory PCR test. Participants with a COVID-19 diagnosis also reported on existing chronic health conditions, body mass index (BMI), and number of persons inside the family unit infected before or after the CPAP-treated patient. Descriptive statistics, Chi-squared tests and Wilcoxon tests were conducted for comparisons.

A total of 15306 individuals from 93 metropolitan departments, covering most of France, with differing burdens of COVID-19 outbreak participated in the study. The data were analysable for 13994 individuals (figure 1). Patients self-reported moderate (20.7%) to severe (46%) OSA, with 99.3% of included subjects being treated with CPAP and 0.7% with oral appliances. The overall population was predominately male (67.1%) with 22.6% aged 51–60 years and 61.9% older than 60 years. 464 (3.3%) indicated suspected or proven (53 out of 464, 11.4%) COVID-19 infection. During the COVID-19 outbreak only a small percentage (15.2%) of CPAP-treated patients received specific advice regarding the COVID-19 outbreak and CPAP use by obstructive sleep apnoea patients. Mainly only those with suspected or proven COVID-19 stopped CPAP use, sometimes without a physician’s advice, and were more likely to move to a separate bedroom. https://bit.ly/2RxQDZO

Cite this article as: Pépin J-L, Sauvaget O, Borel JC, et al. Continuous positive airway pressure-treated patients’ behaviours during the COVID-19 crisis. ERJ Open Res 2020; 6: 00508-2020 [https://doi.org/10.1183/23120541.00508-2020].

Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
usage. Information mainly came from homecare providers (84.9%) and respiratory physician prescribers (6.6%). Only 11.8% had benefited from teleconsultations with respiratory physicians during the crisis.

During the COVID-19 health crisis, 590 (4.4%) have stopped CPAP treatment. Discontinuing CPAP treatment followed a physician’s request (n=21, 3.8%) after confirmation or suspicion of COVID-19 infection (15 patients) and during hospitalisation for COVID-19 infection (six patients). 174 (31.5%) patients stopped their treatment without medical advice, as a precaution and on their own initiative because they were experiencing symptoms evoking COVID-19 (73 patients) or were free of symptoms but were not willing to risk contamination of household members (101 patients). 64.7% of respondents ticked the answer “other”, with some adding a free text explanation. Of patients discontinuing CPAP, 33% and 42%, respectively, of those stopping at their own initiative were living either alone or with one or more persons.

Regarding sleeping arrangements, only 4.5% have started to sleep in separate rooms since the beginning of the outbreak, 69.8% were still sleeping in the same room and 14.5% continued their previous behaviour of sleeping in two separate rooms.

The CPAP-treated subgroup infected with COVID-19 (median BMI 30.7 kg·m\(^{-2}\); interquartile range 27–35 kg·m\(^{-2}\); type 2 diabetes: 14%; hypertension: 38%; asthma: 15.6%) reported essentially moderate disease with only 24 (5.2%) requiring hospitalisation, including six intensive care unit (ICU) admissions. A higher percentage of infected patients discontinued CPAP (21.8 versus 4% infected versus non-infected patients, respectively, p<0.01). To minimise risks to household members, a higher percentage of infected patients moved to a separate bedroom (17.7 versus 4.2%, infected versus non-infected patients respectively, p<0.01). The rate of household members infected after diagnosis in a CPAP-treated patient was similar to the rate of contamination before diagnosis in the CPAP-treated patient.

This survey is the first to assess knowledge, attitudes and behaviours of CPAP-treated patients in response to the COVID-19 pandemic. The prevalence rate of CPAP-treated patients with suspected or proven infection with COVID-19 was 3.3%. This is equivalent to the proportion of the French population infected during the same period of time [8]. The burden of COVID-19 marginally affected CPAP treatment and behaviours with only 4.4% and 4.5% of patients discontinuing CPAP or starting to sleep in separate rooms.
rooms, respectively. These percentages went up to ~20% in cases of suspected or proven COVID-19 infection suggesting that the CPAP associated risk for household members was unknown or underappreciated. An acknowledged recommendation in this situation is not only self-isolation, but also implementation by homecare providers of non-vented CPAP masks with a viral filter, reducing the spread significantly during CPAP treatment [5–7].

We found that 28 out of 464 (6%) of CPAP-treated patients with suspected or proven infection were hospitalised, which again is consistent with the 3.9% and 8%, respectively, reported in a representative male French population in the range of 50–59 and 60–69 years [8]. Once hospitalised, on average in France for the same subgroups, 33% and 37% of patients entered ICU [8], compared with six out of 28 (21.4%) in our survey. Overall, our data do not suggest any obvious increase in risk associated with sleep apnoea. The majority of survey responders were regular CPAP users and a large majority continued treatment during the COVID-19 outbreak potentially limiting the negative impact of untreated OSA. However, there is a possibility of bias as subgroups with long-lasting hospitalisations or early death were not included in the survey. The percentage of survey responders was low and we cannot exclude a selection bias; nevertheless the responding population was nearly 14 000. Moreover, in the open text replies nearly 65% of those who stopped reported the usual reasons leading to CPAP discontinuation outside a pandemic period, i.e. psychological reasons, discomfort and side-effects. These potential limitations to the representativeness of the sample must be addressed by designing exhaustive sampling methods of administrative databases combining OSA diagnosis and hospitalisations for COVID-19.

This large national survey highlights the limited impact of the COVID-19 pandemic on CPAP user behaviours; in agreement with limited changes in CPAP adherence objectively assessed by telemonitoring and probably related to sleep habits during lockdown [9]. Such a health crisis underlines the importance of coordinating management and patient education among all caregivers involved in CPAP long-term home treatment.

Jean-Louis Pépin1,2,7, Odile Sauvaget3,7, Jean Christian Borel4, Christine Rolland5, Marc Sapéne6, Ines Amroussia1,2, Sébastien Bailly1,2,8 and Renaud Tamisier1,2,8

1HP2 laboratory, INSERM U1042, University Grenoble Alpes, Saint-Martin-d’Heres, France. 2EFCR Laboratory, Grenoble Alpes University Hospital, Grenoble, France. 3Alliance Apnées Patients association, Bordeaux, France. 4AGIR à dom. Homecare charity, Meylan, France. 5Association Asthma & Allergies, Grenoble, France. 6Sleep Apnoea Exploration Unit, Bel-Air Clinic, Bordeaux, France. 7Co-first authors. 8Co-senior authors.

Correspondence: Jean-Louis Pépin, Laboratoire EFCR, CHU de Grenoble Alpes, CS10217, 38043, Grenoble, France. E-mail: jpepin@chu-grenoble.fr

Received: 20 July 2020 | Accepted after revision: 10 Sept 2020

Acknowledgement: We thank Alison Foote (Grenoble Alpes University Hospital, Grenoble, France) for critically editing the manuscript.

Data availability: Survey data can be made available for academic research purposes by reasonable request to the corresponding author.

Support statement: J-L. Pépin, R. Tamisier, I. Amroussia and S. Bailly are supported by the French National Research Agency in the framework of the “Investissements d’avenir” program (ANR-15-IDEX-02) and the “e-health and integrated care and trajectories medicine and MIAI artificial intelligence” Chairs of excellence from the Grenoble Alpes University Foundation. This work has been partially supported by MIAI @ Grenoble Alpes. (ANR-19-P3IA-0003). Funding information for this article has been deposited with the Crossref Funder Registry.

Conflict of interest: J-L. Pépin reports grants from the French National Research Agency, Grenoble-Alpes University Foundation and MIAI@Grenoble Alpes during the conduct of the study. O. Sauvaget has nothing to disclose. J.C. Borel has nothing to disclose. C. Rolland has nothing to disclose. M. Sapéne has nothing to disclose. I. Amroussia has nothing to disclose. S. Bailly has nothing to disclose. R. Tamisier has nothing to disclose.

References

1 Benjafiel AV, Pepin JL, Valentine K, et al. Compliance after switching from CPAP to bilevel for patients with non-compliant OSA: big data analysis. BMJ Open Respir Res 2019; 6: e000380.
2 Levy P, Kohler M, McNicholas WT, et al. Obstructive sleep apnoea syndrome. Nat Rev Dis Primers 2015; 1: 15015.
3 Pepin JL, Timisit JP, Tamisier R, et al. Prevention and care of respiratory failure in obese patients. Lancet Respir Med 2016; 4: 407–418.
4 McSharry D, Malhotra A. Potential influences of obstructive sleep apnea and obesity on COVID-19 severity. J Clin Sleep Med 2020; 16: 1645.
Baker JG, Sovani M. Case for continuing community NIV and CPAP during the COVID-19 epidemic. Thorax 2020; 75: 368.

Barker J, Oyefeso O, Koeckerling D, et al. COVID-19: community CPAP and NIV should be stopped unless medically necessary to support life. Thorax 2020; 75: 367.

Krishnan V. COVID-19 and home positive airway pressure (PAP) therapy. Am J Respir Crit Care Med 2020; 201: 28–29.

Salje H, Tran Kiem C, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France. Science 2020; 369: 208–211.

Attias D, Pepin JL, Pathak A. Impact of COVID-19 lockdown on adherence to continuous positive airway pressure (CPAP) by obstructive sleep apnoea patients. Eur Respir J 2020; 56: 2001607.